TrialNature communications2026

Low dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trial.

Xia Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.